Please login to the form below

Not currently logged in
Email:
Password:

Double-dose of cancer drug fails to meet target

Novartis has failed to prove that higher measures of its cancer drug, Glivec are more effective than the current dosage
Novartis has failed to prove in clinical trials that higher measures of its cancer drug, Glivec are more effective than the current dosage.

Trials of 800mg doses of Glivec in patients with chronic myeloid leukaemia (CML), showed no statistically significant improvement to patients treated with the standard 400mg dose.

The higher dose did however have an effect when used as the primary treatment for newly diagnosed patients with clinical milestones achieved significantly faster than with the 400mg dose.

"[The trial] reaffirms Glivec as the standard of care for newly diagnosed CML patients," said Dr Jorge Cortes, professor of medicine and deputy chair of Leukemia at the University of Texas. "We see a strong trend for rapid response with the 800mg doseÖ further follow up will be needed to assess what this rapid early response will mean in terms of long-term benefit."

13th June 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
COUCH.

WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...

Latest intelligence

How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...
Medopad: the up and coming unicorn transforming remote patient monitoring
Blue Latitude Health speaks to Medopad’s Martha Carruthers to learn how the start-up’s modular apps are helping patients with complex diseases....

Infographics